Also from this source

You just read:

BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Origin Biosciences to Develop and Commercialize Therapy

News provided by

BridgeBio Pharma

Jun 11, 2018, 08:00 ET